CRP and cancer: Clinical human studies generally use C-reactive protein (CRP) as a marker of low-grade, systemic inflammation (5, 7), and previous studies have shown that mildly elevated CRP is associated with an increased risk of metabolic syndrome (8), diabetes (9), impaired cognitive function (10), coronary heart disease (11), and cancer (12).